We use cookies and other tracking technology to improve your browsing experience on our website, to show you personalized content, to analyze our website traffic, and to understand where our visitors are coming from. By browsing our website or clicking Accept Cookies, you consent to our use of cookies and other tracking technologies. Read our Privacy Policy

PHARMACEUTICAL INDUSTRY SURVEY

Verified clinicians, payers and KOLs: surveyed at scale.

Book A Demo

GET A CUSTOM QUOTE

Pharmaceutical decisions carry unique weight. GrapeData reaches the world's most gatekept respondents: authenticated against LinkedIn, screened by VerifAI, and available for follow-up expert calls in the same project.

THE STRUCTURAL PROBLEM

Standard panels can't reach real, practising clinicians.

Clinicians, pharmacists, payers and KOLs are among the most time- constrained, gatekept respondents in the world. Online panels inflate counts with non-practising or unverifiable respondents; expert networks are prohibitively expensive for quantitative work. GrapeData verifies every pharmaceutical respondent through their LinkedIn profile before participation: producing data that regulators, medical affairs teams and investment committees can defend, not just publish.

Who we reach

Oncologists, cardiologists & specialists
Primary care physicians & specialty nurses
Pharmacists & hospital procurement leads
Payer & reimbursement decision-makers
KOLs across US, Europe, APAC & LatAm

FROM VALIDATION TO LAUNCH READINESS

Pharmaceutical research across the product lifecycle

GrapeData supports rigorous research at every stage: from early therapy-area scoping through post-launch tracking.

Therapy area assessment

Unmet-need identification across approved and pipeline indications.

Pricing research

Willingness to prescribe and payer reimbursement thresholds.

Message & concept testing

Pre-launch positioning validated directly with HCPs.

Competitor benchmarking

Approved and pipeline therapies compared head-to-head.

Patient journey validation

Treatment-flow mapping with verified practising clinicians.

Launch readiness & tracking

Pre-launch readiness plus post-launch tracking across markets.

Quant, then qual: same respondents

Run quantitative pharmaceutical surveys at statistically robust sample sizes, then escalate to follow-up expert calls with the same respondents for deeper insight.

Example: a 200-respondent oncologist survey doesn't stop at a slide deck: the five most insightful respondents are available for one-to-one calls within days.

METHODOLOGY

Quantitative rigour with qualitative depth.

GrapeData closes the loop between signal and story: bridging survey data and expert interviews without rebuilding the sample through a separate expert network.

GLOBAL & REGULATORY - AWARE

Compliant fieldwork in every market

Pharmaceutical research has compliance requirements that vary by country. GrapeData fields across regulated markets with appropriate screening, fair-market-value honoraria and audit- ready documentation.

English

German

French

Spanish

Italian

Japanese

Mandarin

Portuguese

+ more on request

WHY GRAPEDATA

Why leading firms choose us for pharma research

LinkedIn-verified panel

Proprietary panel of pharmaceutical and healthcare professionals.

Full HCP coverage

Clinicians, pharmacists, payers, hospital procurement and KOLs.

VerifAI screening

Removes non-practising or fraudulent healthcare responses.

Follow-up expert calls

With the same verified HCP respondents from your survey.

Regulatory-aware fieldwork

Fair-market-value honoraria across global markets.

White-glove management

From medical affairs briefing through final delivery.

HOW IT WORKS

From briefing to defensible insight

Briefing & design

Medical affairs briefing, questionnaire design and market scoping.

Verified fielding

LinkedIn-authenticated HCPs, VerifAI- screened, compliant honoraria.

Quant analysis

Statistically robust results across specialties and markets.

Follow-up calls

One-to-one expert calls with your most insightful respondents.

F A Q

Frequently asked questions about pharmaceutical industry survey

How are pharmaceutical survey respondents verified?

Every HCP respondent is authenticated against their LinkedIn profile before participating, confirming specialty, seniority and institution. VerifAI then cross-checks metadata and screens out non-practising or inconsistent responses: producing data that is defensible, traceable and audit-ready.

What pharmaceutical specialties can be reached?

The panel covers primary care, oncology, cardiology, neurology, endocrinology, dermatology, psychiatry, rare diseases, pharmacy, nursing, hospital procurement and payer roles across the US, Europe, APAC and Latin America. Niche specialties and KOL-level respondents are available through targeted recruitment.

Can global pharmaceutical launch research be supported?

Yes. GrapeData fields pharmaceutical surveys across multiple markets in parallel, with localised questionnaires, compliant honoraria and audit-ready documentation. Typical launch readiness studies cover five to fifteen markets with quantitative sampling plus follow-up expert calls in priority geographies.

How do follow-up expert calls work after a pharmaceutical survey?

Within the same project, you can identify specific survey respondents, such as the most insightful oncologists, and schedule one-to-one expert calls with them through GrapeData. This bridges quantitative and qualitative research without rebuilding the sample through a separate expert network.

Is pharmaceutical research compliant with industry standards?

Yes. Fieldwork includes appropriate HCP screening, fair market value honoraria benchmarked to market standards, and audit-ready documentation for medical affairs and compliance teams. GrapeData supports regulatory expectations across the US, EU, UK and major APAC markets.